Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.

Pharmacogenetics - 1 Aug 2002

Schwab Matthias, Schäffeler Elke, Marx Claudia, Fischer Christine, Lang Thomas, Behrens Christoph, Gregor Michael, Eichelbaum Michel, Zanger Ulrich M, Kaskas Bernd A

Abstract excerpt

The efficacy of the immunosuppressants azathioprine and 6-mercaptopurine has been well established in the therapy of inflammatory bowel diseases (IBD). However, its use has been complicated by a high incidence of serious adverse drug reactions such as hematotoxicity, hepatotoxicity, pancreatitis and gastrointestinal disturbances. Whereas azathioprine-related pancytopenia has been clearly linked to thiopurine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Azathioprine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colitis, Ulcerative

Share to Crohn Disease

Share to Immunosuppressive Agents

Share to Methyltransferases

Share to Neutropenia

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 12172211
DOI: 10.1097/00008571-200208000-00003

Genes

TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.PMID 12172211Read ↗

The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases.Semantic proximity Read ↗

Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease PatientsSemantic proximity Read ↗

Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease.Semantic proximity Read ↗

Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT.Semantic proximity Read ↗

Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease.Semantic proximity Read ↗

Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel diseaseSemantic proximity Read ↗

Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.Semantic proximity Read ↗

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.Semantic proximity Read ↗

Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease.Semantic proximity Read ↗

Update on thiopurine pharmacogenetics in inflammatory bowel disease.Semantic proximity Read ↗

Review article: thiopurines in inflammatory bowel disease.Semantic proximity Read ↗

Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.